Literature DB >> 3182782

Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer.

H Maeda1, Y Matsumura, H Kato.   

Abstract

Kinins in the ascitic fluid from a patient with gastric cancer were purified by gel filtration and reversed-phase high-performance liquid chromatography (HPLC). Two fractions (fractions I and II) showed kinin activity. Fraction I did not correspond to either bradykinin or other known kinins, whereas fraction II corresponded to bradykinin. Fraction I contained 8 amino acid residues from bradykinin minus 1 proline plus 1 additional hydroxyproline. Sequence analysis of fraction I showed that the proline at the third amino acid residue of bradykinin was replaced by hydroxyproline. The retention time of fraction I on reversed-phase HPLC was exactly the same as that of synthetic [hydroxyprolyl3]bradykinin (Arg-Pro-Hyp-Gly-Phe-Ser-Pro-Phe-Arg) and was distinguishable from des-Pro3-bradykinin. Thus, these results demonstrate for the first time the presence of [hydroxyprolyl3]bradykinin in vivo. This is also the first report of the presence of bradykinin in human tumor ascites.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3182782

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors.

Authors:  Jun Fang; Haibo Qin; Hideaki Nakamura; Kenji Tsukigawa; Takashi Shin; Hiroshi Maeda
Journal:  Cancer Sci       Date:  2012-01-16       Impact factor: 6.716

2.  Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: analysis by HPLC.

Authors:  Y Matsumura; H Maeda; H Kato
Journal:  Agents Actions       Date:  1990-03

3.  Biodistribution and targeting potential of poly(ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model.

Authors:  Goldie Kaul; Mansoor Amiji
Journal:  J Drug Target       Date:  2004       Impact factor: 5.121

4.  Bradykinin binding sites in healthy and carcinomatous human lung.

Authors:  A Trifilieff; E Lach; P Dumont; J P Gies
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

Review 5.  Drug delivery and transport to solid tumors.

Authors:  Seong Hoon Jang; M Guillaume Wientjes; Dan Lu; Jessie L S Au
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

Review 6.  Biological rationale for the design of polymeric anti-cancer nanomedicines.

Authors:  Yan Zhou; Jindřich Kopeček
Journal:  J Drug Target       Date:  2012-09-26       Impact factor: 5.121

7.  Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system.

Authors:  Yu Sakurai; Hiroto Hatakeyama; Yusuke Sato; Mamoru Hyodo; Hidetaka Akita; Hideyoshi Harashima
Journal:  Mol Ther       Date:  2013-04-09       Impact factor: 11.454

8.  Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.

Authors:  Anjali Apte; Erez Koren; Alexander Koshkaryev; Vladimir P Torchilin
Journal:  Cancer Biol Ther       Date:  2013-10-21       Impact factor: 4.742

Review 9.  Humoral innate immune response and disease.

Authors:  Stephanie N Shishido; Sriram Varahan; Kai Yuan; Xiangdong Li; Sherry D Fleming
Journal:  Clin Immunol       Date:  2012-06-18       Impact factor: 3.969

10.  Plasma Metabolomics Analysis of Polyvinyl Chloride Workers Identifies Altered Processes and Candidate Biomarkers for Hepatic Hemangiosarcoma and Its Development.

Authors:  John J Guardiola; Josiah E Hardesty; Juliane I Beier; Russell A Prough; Craig J McClain; Matthew C Cave
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.